Lv7
4980 积分 2022-04-26 加入
Overcoming asciminib resistance by targeting compound BCR::ABL1 mutations in chronic myeloid leukemia
3天前
求助中
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action
3天前
已完结
LPA81: Discovery of an Exceptionally Potent Protac Degrading Native and Mutant BCR-ABL1 Oncoprotein in CML
4天前
求助中
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug
4天前
已完结
CML-575: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia
7天前
已关闭
CML-586: Effect of TERN-701 on Transporter and Cytochrome P450 Probe Substrates and the Effect of Acid-Reducing Agents on TERN-701 Pharmacokinetics
7天前
已关闭
Tern-701 (HS-10382) Is a Potent Inhibitor of BCR::ABL1 and Is Synergistic with Active Site Tyrosine Kinase Inhibitors
7天前
已关闭
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
8天前
已完结
[Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review]
9天前
已完结
皖公网安备34019202002308
